Upon joining the study, you will be required to sign a document called an informed consent form. This document confirms that you understand the study and agree to participate.

You must be at least 18 years old and have been diagnosed with prurigo nodularis for at least three months before the study begins.

An initial assessment will be conducted to ensure you meet the study criteria. This includes having at least six itchy skin lesions on two different body areas, such as both legs.

Your skin condition will be evaluated using a scoring system, and you will need to have a certain score to participate.

You will be randomly assigned to receive either the ruxolitinib cream or a vehicle cream, which looks the same but does not contain the active ingredient.

The ruxolitinib cream is applied to the skin twice a day, once in the morning and once in the evening, for a period of 12 weeks.

Throughout the study, you will have weekly assessments to monitor your progress. This includes evaluating the severity of your skin condition and any changes in symptoms.

You will be asked to report any side effects or changes in your condition during these assessments.

At week 12, a primary evaluation will be conducted to determine the effectiveness of the treatment. This involves measuring the improvement in your skin condition using a specific scoring system.

The goal is to achieve a significant reduction in the severity of your symptoms.

Additional evaluations will be conducted at week 4 and day 7 to assess early responses to the treatment.

These evaluations help to understand how quickly the treatment is working and its overall effectiveness.

At the end of the study, you will have a final assessment to review your overall experience and any changes in your condition.

You will be provided with information on the next steps and any follow-up care that may be needed.